Continuing Education
Activity release date: 2/15/2010
Activity expiration date: 2/15/2011
CME Post-Test
CME Post-Test and Evaluation
ABOUT THE ACTIVITY
This activity is based on articles and reports in ONCOLOGY Nurse Edition. It is developed from an identifi ed educational need for information about practical management issues in medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.
If you haven't read this month's issue of ONCOLOGY or would like to review the articles online, click on the links below:
Integrating Genetics and Genomics Into Oncology Nursing
After reading this issue of ONCOLOGY Nurse Edition, participants should be able to:
- Explain the roles that genetics and genomics play in health and disease, including cancer.
- Highlight key genetic and genomic research projects that are further illuminating the genetic basis of cancer.
- Describe ways in which genetic and genomic information can be used in cancer screening, diagnostics and prognostics, and treatment selection.
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME LLC and The Oncology Group. CME LLC is accredited by the ACCME to provide continuing medical education for physicians. CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
This program is coprovided by the Boston College William F. Connell School of Nursing Continuing Education Program, Chestnut Hill, MA. Boston College School of Nursing Continuing Education Program is approved as a provider of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Participants must read the entire educationa activity for contact hours.
COMPLIANCE STATEMENT
This activity is an independent educational activity under the direction of CME LLC. It was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions With Healthcare Professionals, assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
However, CME LLC, the Grantor, and CMP Medica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may refl ect the clinical experience of the author(s), or
they may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information. The opinions and recommendations herein are those of the author(s) and do not necessarily reflect the views of the providers or producer.
FINANCIAL DISCLOSURES
Please refer to each article and editorial commentary.
COPYRIGHT
© Copyright 2009. Copyrights owned by CME LLC. All rights reserved.
CONTACT INFORMATION:
Director, Continuing Medical Education
CME LLC
Harborside Financial Center
Plaza 3, Suite 806
Jersey City, NJ 07311
Phone: 888-618-5781
Fax: 201-946-0700
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
